Rheumatology, Gout & Immunosuppressants
Biosimilars of anti-TNF agents are one of India's strongest high-value export stories.
What This Class Covers
Disease-modifying antirheumatic drugs and a fast-growing roster of biosimilar biologics (adalimumab, etanercept, infliximab and others) sell at a large discount to originator pricing in Tier 2 and 3 markets. Transplant immunosuppressants need narrow-therapeutic-index bioequivalence data, so manufacturer selection matters more here than in ordinary generics.
Prescription Status Notes
1 of 49 molecules is OTC.
Full Molecule List
Abatacept
Adalimumab
Anakinra
Antithymocyte globulin
Apremilast
Auranofin
Azathioprine
Baricitinib
Basiliximab
Belatacept
Belimumab
Canakinumab
Certolizumab pegol
Colchicine
Cyclophosphamide (rheum)
Cyclosporine
D-Penicillamine
Deflazacort
Diacerein
Etanercept
Everolimus
Filgotinib
Glucosamine + Chondroitin
Golimumab
Guselkumab
Hyaluronic acid intra-articular
Hydroxychloroquine
Infliximab
Ixekizumab
Leflunomide
Methotrexate
Mycophenolate mofetil
Mycophenolate sodium
Pegloticase
Platelet-rich plasma kits
Prednisolone (rheum)
Probenecid
Risankizumab
Rituximab (RA)
Secukinumab
Sirolimus
Sulfasalazine
Sulfinpyrazone
Tacrolimus
Thymoglobulin
Tocilizumab
Tofacitinib
Upadacitinib
Ustekinumab
No molecules match your search.
Showing 49 of 49 molecules tracked in this class. Contact us for a specific molecule not listed here.
Prescription Breakdown
- OTC
- 1
- Prescription (Rx)
- 48
- Restricted / Controlled
- 0
Need a Molecule Not Listed Here?
Our manufacturing-partner network covers a broad range beyond this catalogue. Send us your requirement.